Use of New Bacterial Enzymes to Improve Nitro-Prodrug Cancer Therapy
使用新型细菌酶改善硝基前药癌症治疗
基本信息
- 批准号:7552002
- 负责人:
- 金额:$ 32.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-01-07 至 2010-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAffinityAnimalsAntineoplastic AgentsArtsAttenuatedAutoradiographyBacteriaBacterial GenesBiochemistryBiologyBiometryBlood VesselsCD44 geneCancer cell lineCancerousCellsCharacteristicsChemicalsChemistryChemotherapy-Oncologic ProcedureClinical TrialsCoagulation ProcessCollaborationsCritiquesDetectionDoseDrug Delivery SystemsDrug KineticsDrug usageEffectivenessElectronic MailEnzymesEvolutionExcisionFluorescent ProbesHumanHyaluronanHypoxiaImageImageryImaging technologyIn VitroInterdisciplinary StudyInvestigationIsraelKiller CellsLabelLifeLightLiposomesMalignant NeoplasmsMetabolicMethodsMicroscopicMitomycinsMusNQO1 geneNecrosisNitro CompoundsNitroreductasesNormal CellOpticsPenetrationPharmaceutical PreparationsPharmacotherapyProcessProdrugsPropertyPublic HealthQuinonesSalmonella typhimuriumScientistSolidSolid NeoplasmStaining and LabelingStaining methodStainsSuggestionSystemTelephoneTestingTherapeuticToxic effectVariantWorkbasecancer cellcancer therapycatalystcell killingchemotherapycollagenasecytokineefficacy testingexperienceimprovedin vivokillingsmedical schoolsmolecular imagingneoplastic cellnoveloverexpressionphenoxazinepreventreceptorrestorationtargeted deliverytumor
项目摘要
DESCRIPTION (provided by applicant): Reductive prodrugs are harmless in their native state but kill both growing and non-growing tumor cells upon reduction. Cancer cure requires selective killing of all cancerous cell with minimal side effects, but this is rarely achieved because most drugs cannot reach all the cells within solid tumors (present in >90% human cancers), and are not selective, being activated also by normal human cells. Thus, a drug/catalyst regime is needed that specifically targets tumors and permits visualization of tumor barriers to drug penetration. This proposal is concerned with a newly discovered nitro-prodrug [6-chloro-9-nitro-5-oxo-5H-benzo[a]phenoxazine (CNOB)] and an evolved high-activity nitroreductase discovered and evolved by the PI. CNOB is an effective drug with the unique quality that its activated product is fluorescent and can be visualized in living animals. Novel methods of drug/catalyst delivery to tumors and removal of tumor barriers are also proposed. Four aims will be pursued. The first two involve in vitro studies: the generality of effectiveness against different cancers, and identification of metabolites. Aim 3 deals with specific delivery of the drug/catalyst to tumors. Hyaluronan-labeled nanoliposomes that target the CD44 receptor over-expressed in nearly all cancers will be used to deliver the drug, the catalyst, or both. However, since some normal cells could also express CD44, harmful non-target delivery could occur. Another approach will therefore also be employed that targets two receptors typically overexpressed in cancer cells. While normal cells may express one of these receptors, they would be highly unlikely to express both. In this approach, CNOB will be delivered by CD44-targeting liposomes, and the catalyst by the cytokine induced killer cells that target the tumor-specific NKG2D receptors. This way the normal cells might receive one or the other component of this therapy (the drug or the catalyst) but not both, thus escaping harm. The pharmacokinetics of the drug will be examined for the delivery methods. Aim 4 will dissect the drug and activated product reach within the tumors and will utilize state of the art microscopic and in vivo imaging technology (confocal, IVIS, intravital, autoradiography of tumor sections) and staining (differential fluorescent labels, staining of blood vessels, regions of hypoxia and necrosis) to detect the tumor regions hindering penetration. Removal of these barriers will be attempted by, for example, use of collagenases to dissolve clots, and restoration of normal vasculature in the tumor. Effective means for treating cancer in mice will result, paving the way for human trials of this exciting new cancer therapy. Relevance to public health. Cancer drugs are often unsatisfactory for two reasons: they also harm the non-cancerous cells; and they fail to kill all the cells within a tumor. The drug under study is harmless to normal cells, and will kill cancer cells because a specially developed enzyme will be delivered specifically only to them. This drug can also be seen inside the body; this will allow detection of penetration barriers within the tumors and their elimination.
说明书(申请人提供):还原前体药物在天然状态下是无害的,但在还原时既能杀死生长中的肿瘤细胞,也能杀死不生长的肿瘤细胞。癌症治疗需要选择性地杀死所有的癌细胞,副作用最小,但这很少实现,因为大多数药物不能到达实体肿瘤中的所有细胞(存在于90%的人类癌症中),而且没有选择性,也可以被正常的人类细胞激活。因此,需要一种专门针对肿瘤的药物/催化剂体系,并允许可视化肿瘤对药物渗透的障碍。这项建议涉及新发现的硝基前药[6-chloro-9-nitro-5-oxo-5H-benzo[a]phenoxazine(CNOB)]和由PI发现和进化的一种进化的高活性硝基还原酶。CNOB是一种有效的药物,其独特的性质是其激活的产物是荧光的,并且可以在活体动物身上看到。还提出了将药物/催化剂输送到肿瘤和清除肿瘤屏障的新方法。我们将追求四个目标。前两项涉及体外研究:针对不同癌症的有效性的普遍性,以及代谢物的鉴定。AIM 3涉及药物/催化剂对肿瘤的特定递送。针对CD44受体在几乎所有癌症中过度表达的透明质酸标记纳米脂质体将被用于输送药物、催化剂或两者兼而有之。然而,由于一些正常细胞也可以表达CD44,因此可能会发生有害的非靶向传递。因此,还将采用另一种方法,针对通常在癌细胞中过度表达的两种受体。虽然正常细胞可能表达其中一种受体,但它们极不可能同时表达两种受体。在这种方法中,CNOB将由CD44靶向脂质体递送,并由细胞因子诱导的针对肿瘤特异性NKG2D受体的杀伤细胞作为催化剂。这样,正常细胞可能会接受这种疗法的一种或另一种成分(药物或催化剂),但不会同时接受两者,从而逃脱伤害。对于给药方法,将检查药物的药代动力学。AIM 4将解剖肿瘤内的药物和活化产物REACH,并将利用最先进的显微和活体成像技术(共焦、IVIS、活体内成像、肿瘤切片的放射自显影)和染色(差异荧光标记、血管染色、缺氧和坏死区域)来检测阻碍穿透的肿瘤区域。清除这些屏障的方法是,例如,使用胶原酶溶解凝块,恢复肿瘤中的正常血管系统。治疗老鼠癌症的有效方法将会产生,为这种令人兴奋的新癌症疗法的人类试验铺平道路。与公共卫生的相关性。抗癌药物通常不能令人满意,原因有两个:它们也会伤害非癌细胞;它们不能杀死肿瘤内的所有细胞。正在研究的药物对正常细胞无害,但会杀死癌细胞,因为一种特殊开发的酶将只对癌细胞产生特异性作用。这种药物也可以在体内看到;这将允许检测肿瘤内的渗透屏障并消除它们。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AC Matin其他文献
AC Matin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AC Matin', 18)}}的其他基金
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
用于酶前药治疗的 HER2 靶向外泌体递送治疗性 mRNA
- 批准号:
9333460 - 财政年份:2016
- 资助金额:
$ 32.83万 - 项目类别:
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
用于酶前药治疗的 HER2 靶向外泌体递送治疗性 mRNA
- 批准号:
9063182 - 财政年份:2013
- 资助金额:
$ 32.83万 - 项目类别:
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
用于酶前药治疗的 HER2 靶向外泌体递送治疗性 mRNA
- 批准号:
8708235 - 财政年份:2013
- 资助金额:
$ 32.83万 - 项目类别:
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
用于酶前药治疗的 HER2 靶向外泌体递送治疗性 mRNA
- 批准号:
8846440 - 财政年份:2013
- 资助金额:
$ 32.83万 - 项目类别:
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
用于酶前药治疗的 HER2 靶向外泌体递送治疗性 mRNA
- 批准号:
8582016 - 财政年份:2013
- 资助金额:
$ 32.83万 - 项目类别:
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
用于酶前药治疗的 HER2 靶向外泌体递送治疗性 mRNA
- 批准号:
8901333 - 财政年份:2013
- 资助金额:
$ 32.83万 - 项目类别:
Development of Contrast Agents from Bacterial Magnetite for Targeting and Visuali
用于靶向和可视化的细菌磁铁矿造影剂的开发
- 批准号:
7707130 - 财政年份:2009
- 资助金额:
$ 32.83万 - 项目类别:
Development of Contrast Agents from Bacterial Magnetite for Targeting and Visuali
用于靶向和可视化的细菌磁铁矿造影剂的开发
- 批准号:
7813860 - 财政年份:2009
- 资助金额:
$ 32.83万 - 项目类别:
Use of New Bacterial Enzymes to Improve Nitro-Prodrug Cancer Therapy
使用新型细菌酶改善硝基前药癌症治疗
- 批准号:
7742185 - 财政年份:2008
- 资助金额:
$ 32.83万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 32.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 32.83万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 32.83万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 32.83万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 32.83万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 32.83万 - 项目类别:
Discovery Grants Program - Individual